On August 21, 3SBIO rose 5.58% in regular trading, trading at HKD 17.45/share, with turnover of HKD 198 million.

On the news front, the company released its H1 interim results on August 20, reporting revenue of RMB 4.53 billion, up 3.9% year-over-year. While attributable net profit declined 15.6% to RMB 1.15 billion, the adjusted operating attributable net profit rose 26.5% to RMB 1.44 billion. Overseas product sales surged 43% year-over-year, with core products securing marketing approvals across 23 countries globally. R&D expenditure increased 24.9% to RMB 680 million, reflecting the company's commitment to innovation-driven growth. Additionally, China's National Medical Products Administration officially approved the company's non-steroidal anti-inflammatory drug application on August 20, further strengthening its competitive positioning in the anti-inflammatory and analgesic segment. The company reported financial resources of RMB 19.4 billion, providing a solid foundation for continued R&D investment and strategic expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)